Serum institute

SII seeks nod to export 32.4 lakh doses of its Covid vaccine Covovax to US

The sources said it will be the first instance of any Indian manufacturer's vaccine -- Covid or non-Covid -- to be exported to the US.

published on : 30th June 2022

NTAGI to review trial data on Serum Institute's qHPV vaccine against cervical cancer

A separate HPV working group of the National Technical Advisory Group on Immunisation (NTAGI) had examined on June 8 the clinical trial data and usefulness of the vaccine.

published on : 26th June 2022

Panel for emergency use approval to SII vaccination for 7-11 age group

Officials said the Subject Expert Committee deliberated upon the matter and recommended EUA for use in younger children.

published on : 25th June 2022

Government panel recommends emergency approval for SII's Covovax for 7-11 year olds

The DCGI had approved Covovax for restricted use in emergency situations in adults on December 28 and in the 12 to 17 years age group subject to certain conditions on March 9.

published on : 24th June 2022

Government panel recommends market authorisation for SII's qHPV vaccine against cervical cancer

In the application, Singh is learnt to have stated that qHPV vaccine CERVAVAC has demonstrated robust antibody response that is nearly 1,000 times higher than the baseline.

published on : 15th June 2022

Serum Institute, Symbiosis to set up research centre for vaccine development

The entity will work towards improving health equity against future pandemics and infectious diseases. It will also ensure cross-programme coordination and collaboration.

published on : 13th May 2022

Millions of COVID vaccines unsold; stopped production since December 2021: Adar Poonawalla

He also called for speeding up the decision to vaccinate young kids and said if they can be given other immunisation vaccines why not for the COVID-19.

published on : 22nd April 2022

Poonawalla warns against return to business-as-usual approach 

Calling for increased adoption of booster doses, Poonawalla said it is also needed because people need to travel internally and outside,  many countries have made booster doses mandatory for travel.

published on : 22nd April 2022

Panel seeks more data on Serum Institute's EUA application for Covovax use

The SII had last month submitted an application to the Drugs Controller General of India (DCGI) seeking emergency use authorisation (EUA) for Covovax's use among children in the age group.

published on : 12th April 2022

Serum Institute to give free Covishield vials to private vaccination centres to compensate for price difference

India began administering the precaution dose of COVID-19 vaccines to all beneficiaries aged above 18 years at private vaccination centres from Sunday.

published on : 10th April 2022

Covishield & Covaxin prices cut, hospitals to pay Rs 225 per dose

The precautionary dose has to be of the same vaccine used for the first two doses.

published on : 10th April 2022

Serum Institute, Bharat Biotech cut COVID vaccine prices for private hospitals to Rs 225

The Union Health Ministry on Friday announced that those above the age of 18 years who have completed nine months after the administration of the second dose will be eligible for the precaution dose.

published on : 9th April 2022

Serum Institute's Covishield precaution dose priced at Rs 600 per shot

The Union Health Ministry on Friday announced that those above the age of 18 years who have completed nine months after the administration of the second dose will be eligible for the precaution dose.

published on : 8th April 2022

Low number of COVID-19 cases now as India chose right vaccine, says Poonawalla

Speaking to reporters on the sidelines of the 'Alternate Fuel Conclave', he said the fourth wave, if at all it occurs, will hopefully be mild.

published on : 4th April 2022

SC reserves verdict on plea seeking data on clinical trials of vaccination drives

A petition filed by a former member of the National Technical Advisory Group on Immunisation (NTAGI) Jacob Puliyel sought disclosure of post-vaccination data and clinical trial data. 

published on : 22nd March 2022
1 2 3 4 >